Home > Boards > US OTC > Biotechs >

Endonovo Therapeutics Inc. (ENDV)

Add ENDV Price Alert      Hide Sticky   Hide Intro
Moderator: brojazzy, Craig305
Search This Board: 
Last Post: 4/7/2020 9:36:38 PM - Followers: 205 - Board type: Free - Posts Today: 0


Endonovo Therapeutics Acquires Assets of Electroceuticals Developer, Rio Grande Neurosciences, and Settles Lawsuit



Endonovo to Fund All Currently Planned and Future Clinical Trials for Traumatic Brain Injury, Post-Concussion Syndrome, Stroke and Other Central Nervous System Disorders

LOS ANGELES, CA, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a clinical-stage developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today announced it has acquired the PEMF assets of Rio Grande Neurosciences, Inc. (“RGN”) for $4.5 million and settled its lawsuit concerning RGN’s termination of the binding letter agreement to acquire RGN dated July 8, 2016.

Under the terms of the settlement agreement, RGN paid $150,000 to Endonovo Therapeutics and granted an exclusive option to Endonovo to acquire the PEMF assets of RGN for $4.5 million, which the Company exercised per the settlement agreement. The settlement has resulted in the dismissal of the case in the Superior Court of California, County of Los Angeles.

Endonovo believes settling the case at this time is in the best interest of all parties, and its acquisition of RGN's PEMF assets could result in substantial benefit to its shareholders. 

The PEMF assets includes a portfolio of intellectual property, including 27 issued patents with foreign patent protection covering the therapeutic use of PEMF for the treatment of various central nervous system disorders. Endonovo Therapeutics will initiate and fund both currently planned and all future clinical trials to evaluate the use of PEMF in the treatment of central nervous system disorders, including traumatic brain injury, post-concussion syndrome, stroke and multiple sclerosis.

The PEMF assets additionally include a portable, disposable PEMF device with a CE Mark and an FDA 510(k) clearance for the treatment of soft tissue injuries and post-surgical pain and edema in addition to medical reimbursement for the treatment of chronic wounds. Endonovo Therapeutics will begin the commercialization of the PEMF assets through licensing and joint venture agreements and the creation of various sales channels and distribution agreements.

The Company has posted an overview of the PEMF assets in the presentations page on its investor relations website.

About Traumatic Brain Injury:

Traumatic Brain Injury (TBI), also called craniocerebral trauma is a brain dysfunction caused by an outside force, usually a violent blow to the head. In 2010, approximately 2.5 million people sustained a traumatic brain injury. More than half of all brain injuries are bad enough to require people to go to the hospital. A severe TBI not only affects the quality of life of an individual and their family, but also imposes a large economic toll on society. The economic cost of TBI in 2010 was estimated to be approximately $76.5 billion. Severe brain injuries can lead to permanent brain damage or death. Half of all TBIs are from motor vehicle accidents, with military personnel in combat zones and athletes also being at risk.

About Chronic Wounds:

A chronic wound is a wound that does not heal in an orderly set of stages and in a predictable amount of time the way most wounds do. Wounds that do not heal within three months are often considered chronic. Some of the most common types of chronic wounds include, ischemic wounds, radiation poisoning wounds, surgical wounds and ulcers, such as arterial ulcers, venous ulcers, diabetic ulcers and pressure ulcers. The increasing prevalence of diabetes mellitus is a driving factor in the occurrence of chronic wounds, such as diabetic ulcers. A recent study published in Value in Health, found that approximately 15% of Medicare beneficiaries in 2014 (8.2 million) had at least one type of wound or infection at an estimated cost of nearly $32 billion to CMS. As the US Centers for Medicare and Medicaid Services (CMS) moves toward an outcome-based model, CMS needs to take a careful look at wound care, according to the authors of the study. New, more effective and equally important, more cost effective therapies are needed as the cost associated with treating these chronic wounds continues to rise.   

“We are very excited about this acquisition and the value it will provide our shareholders,” said Endonovo CEO, Alan Collier. “We are adding clinical stage programs and expanding our pipeline of non-invasive electroceuticals into central nervous system disorders, strengthening our intellectual property, and adding market-ready products for the treatment of various soft tissue injuries, post-surgical pain and swelling, as well as chronic wounds,” stated Mr. Collier.

“This acquisition represents a significant milestone for Endonovo and positions the company as the leader in bioelectronic medicine allowing for more favorable financing, uplisting the company’s common stock onto a national stock exchange and providing the company a valuation comparable to other companies in the electrical stimulation/electroceuticals sector,” concluded Mr. Collier.

Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical

Oct 13, 2017

OTC Disclosure & News Service


Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical


Non-Invasive Electroceutical Significantly Increased Cardiac Function and Reduced Ventricular Remodeling in Infarcted Animals

LOS ANGELES, CA--(Marketwired - Oct 13, 2017) -  Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today reported that it has completed a study to evaluate the potential efficacy of its Immunotronics™ platform, a non-invasive electroceutical, in a well-established preclinical model of heart failure (post-MI remodeling). With these positive results, the Company continues to advance the development of its pipeline of non-invasive electroceuticals targeting vascular diseases and inflammatory conditions in vital organs.

The recently completed study investigated the therapeutic efficacy of the Company's Immunotronics™ platform in a widely used mouse model of heart failure (post-MI remodeling). In this model, treatment with the Company's non-invasive electroceutical two or three times per day resulted in significantly increased cardiac function and reduced ventricular remodeling. Treatment with the Company's Immunotronics™ technology two or three times per day resulted in significantly improved Ejection Fraction (EF), Fractional Shortening (FS), Heart Weight-to-Body Weight Ratio (HW/BW), Left Ventricular Diastolic Pressure (LVDP), Left Ventricular End-Systolic Diameter (LVESD), and Interventricular Septal Dimension at Systole (IVSS). The Company will post the data for shareholders on its website shortly.

"Heart failure and vascular diseases are potential clinical targets for our non-invasive electroceuticals. These results demonstrate the incredible potential of electroceutical-based therapies," said Alan Collier, CEO of Endonovo Therapeutics. "We plan to submit our preclinical post-MI remodeling results during 2018 for presentation at a relevant scientific meeting as we continue to advance our class-leading non-invasive electroceuticals toward the clinic."



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#31545  Sticky Note REVERSE STOCK SPLIT 1 FOR 1,000 BUYER BEWARE!!! Biotech_Tradez 10/31/19 11:54:37 AM
#31852   ENDV = PENNY STOCK SCAM!! YOU'VE BEEN WARNED!! Biotech_Tradez 04/07/20 09:23:47 PM
#31851   I am in my early forties sport and Biotech_Tradez 04/07/20 09:22:37 PM
#31850   Look forward young man forward not backwards. don't Monroe1 04/07/20 08:52:30 PM
#31849   You sound confused. What is non-dilutive about reversing Biotech_Tradez 04/07/20 08:45:58 PM
#31848   After 6 months and structured to be non Monroe1 04/07/20 07:25:22 PM
#31847   You’ve been right all along, thanks! Nocateed 04/07/20 07:06:04 PM
#31846   You are buying conversions not the float. Biotech_Tradez 04/07/20 06:47:17 PM
#31845   OMG 7.1 Million what are going to do. Monroe1 04/07/20 04:57:09 PM
#31844   Holy shit. New O/S is 7.1 million. More Biotech_Tradez 04/07/20 12:44:42 PM
#31843   What an absolute scam brojazzy 04/04/20 01:58:34 PM
#31842   ENDV lost period. How bad is to be seen. Biotech_Tradez 04/03/20 02:17:30 PM
#31841   Looks possible that the KVP lawsuit will end Craig305 04/02/20 06:04:37 PM
#31840   I don't think they are even pursing anything Biotech_Tradez 03/27/20 11:49:18 AM
#31839   Endonovo filed a patent on 10/18/19. The publication is Craig305 03/26/20 05:41:03 PM
#31838   BUYER BEWARE!!! ENDV = PENNY STOCK SCHEME!! Biotech_Tradez 03/25/20 01:22:35 PM
#31837   NEW BAG HOLDERS NEEDED TO PAY MANAGEMENT'S SALARIES! Biotech_Tradez 03/25/20 01:21:37 PM
#31836   ENDV "INTENDS", THEY AREN'T DOING ANYTHING!!! LOL!! Biotech_Tradez 03/25/20 01:20:08 PM
#31835   RECYCLING THE SAME FAKE NEWS!! LOL!!! Biotech_Tradez 03/25/20 01:19:09 PM
#31834   Endonovo Therapeutics seeks Intensive Care Unit Partners for davidsson10 03/25/20 08:09:48 AM
#31833   Hence why they are buying "certain" assets not Biotech_Tradez 03/20/20 01:52:43 PM
#31832   That was my initial reaction also...RE: buy ENDV Craig305 03/20/20 01:46:33 PM
#31831   Read it, looks to me like they are Biotech_Tradez 03/20/20 01:39:34 PM
#31830   Wow you had a stock split I see retired early 03/19/20 04:12:28 PM
#31829   Look at this article. https://www.theherrickcompany.com/health-sciences/ Leonar Craig305 03/18/20 10:24:54 PM
#31828   Wow, what an absolute JOKE this scam brojazzy 03/16/20 10:29:51 PM
#31827   NEXT PR = SOFPULSE CURES CANCER!!!!! Biotech_Tradez 03/16/20 01:04:58 PM
#31826   ENDV = PUMP & DUMP SCHEME!! Biotech_Tradez 03/16/20 01:04:22 PM
#31825   ROFL!!! YOU CAN'T MAKE THIS STUFF UP!! Biotech_Tradez 03/16/20 01:03:20 PM
#31824   Took 3 weeks, but here you go. https://ir.endonovo.com/press-releases/detail/28 Craig305 03/16/20 10:15:32 AM
#31823   Covid-19 pr RIGHT ON SCHEDULE Nocateed 03/16/20 08:15:38 AM
#31822   It certainly seemed so. How is this being walked Craig305 03/11/20 12:08:11 PM
#31821   This POS garbage is going to zero brojazzy 03/11/20 12:07:26 AM
#31820   Be advised: Failed to Deliver Threshold Flag at FINRA. ThirdSyte 03/10/20 10:40:15 PM
#31819   NEW OS: 3,322,913 SHARES MORE THAN DOUBLED IN Biotech_Tradez 03/05/20 01:24:51 AM
#31818   Just another red day, nothing to see here brojazzy 03/04/20 04:24:37 PM
#31815   I have no clue what they are paying Biotech_Tradez 03/02/20 02:17:08 PM
#31814   Do you know how much the medical advisors/promoters Craig305 03/02/20 01:28:05 PM
#31813   Maybe they should stop diluting the shit out Biotech_Tradez 03/02/20 10:54:01 AM
#31812   LOL! FAKE NEWS RIGHT ON TIME! Biotech_Tradez 03/02/20 10:46:56 AM
#31811   It was 1.7m shares last month but it Biotech_Tradez 03/02/20 10:45:45 AM
#31810   Wasn't this trading at 3.00 about 20 days midas716 02/28/20 02:27:27 PM
#31809   Hey Bio, what's the latest OS that you Tkmoney1 02/28/20 08:55:48 AM
#31808   The rate of dilution has increased significantly. But Biotech_Tradez 02/27/20 03:25:17 PM
#31807   Why are people buying at the Ask with Craig305 02/27/20 01:50:01 PM
#31806   If NFL buys just 1 unit, we'll see Craig305 02/27/20 01:18:32 PM
#31805   Can you honestly say that buying less than Biotech_Tradez 02/27/20 12:04:47 PM
#31804   PUMP & DUMP PR IMMINENT probably saying Biotech_Tradez 02/27/20 12:01:50 PM
#31803   Ouch, getting UGGGGLY!! That's management for you, bunch brojazzy 02/27/20 11:42:50 AM
#31802   What a shit show. Endocrappo 02/27/20 11:09:32 AM
#31801   We all know that’s just a matter of time brojazzy 02/26/20 10:13:58 PM